Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or a combination?
- PMID: 15649162
- DOI: 10.1111/j.1460-9592.2004.01366.x
Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or a combination?
Abstract
Background: Children with cyanotic heart disease undergoing cardiac surgery in which cardiopulmonary bypass is used are at increased risk of postoperative bleeding. In this study, the authors investigated the possibility of reducing postoperative blood loss by using aprotinin and tranexamic acid alone or a combination of these two agents.
Methods: In a prospective, randomized, blind study, 100 children undergoing cardiac surgery were investigated. In group 1 (n = 25) patients acted as the control and did not receive either study drugs. In group 2 (n = 25) patients received aprotinin (30.000 KIU.kg(-1) after induction of anesthesia, 30.000 KIU.kg(-1) in the pump prime and 30.000 KIU.kg(-1) after weaning from bypass). In group 3 (n = 25) patients received tranexamic acid (100 mg.kg(-1) after induction of anesthesia, 100 mg.kg(-1) in the pump prime and 100 mg.kg(-1) after weaning from bypass). In group 4 (n = 25) patients received a combination of the two agents in the same manner. Total blood loss and transfusion requirements during the period from protamine administration until 24 h after admission to the intensive care unit were recorded. In addition, hemoglobin, platelet counts and coagulation studies were recorded.
Results: Postoperative blood loss was significantly higher in the control group (group 1) compared with children in other groups who were treated with aprotinin, tranexamic acid or a combination of the two agents (groups 2, 3 and 4) during the first 24 h after admission to cardiac intensive care unit (40 +/- 18 ml.kg(-1).24 h(-1), aprotinin; 35 +/- 16 ml.kg(-1).24 h(-1), tranexamic acid; 34 +/- 19 ml.kg(-1).24 h(-1), combination; 35 +/- 15 ml.kg(-1).24 h(-1)). The total transfusion requirements were also significantly less in the all treatment groups. Time taken for sternal closure was longer in the control group (68 +/- 11 min) compared with treatment groups 2, 3 and 4, respectively (40 +/- 18, 42 +/- 11, 42 +/- 13 min, P < 0.05). The coagulation parameters were not found to be significantly different between the three groups.
Conclusions: Our results suggested that both agents were effective to reduce postoperative blood loss and transfusion requirements in patients with cyanotic congenital heart disease. However, the combination of aprotinin and tranexamic acid did not seem more effective than either of the two drugs alone.
Similar articles
-
Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.Anesth Analg. 2008 Nov;107(5):1469-78. doi: 10.1213/ane.0b013e318182252b. Anesth Analg. 2008. PMID: 18931201 Clinical Trial.
-
Tranexamic acid as a means of reducing the need for blood and blood component therapy in children undergoing open heart surgery for congenital cyanotic heart disease.J Med Assoc Thai. 2002 Sep;85 Suppl 3:S904-9. J Med Assoc Thai. 2002. PMID: 12452228 Clinical Trial.
-
Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions.J Thorac Cardiovasc Surg. 2000 Sep;120(3):520-7. doi: 10.1067/mtc.2000.108016. J Thorac Cardiovasc Surg. 2000. PMID: 10962414 Clinical Trial.
-
Aprotinin increases mortality as compared with tranexamic acid in cardiac surgery: a meta-analysis of randomized head-to-head trials.Interact Cardiovasc Thorac Surg. 2009 Jul;9(1):98-101. doi: 10.1510/icvts.2008.198325. Epub 2009 Apr 20. Interact Cardiovasc Thorac Surg. 2009. PMID: 19380335 Review.
-
Lessons from aprotinin: is the routine use and inconsistent dosing of tranexamic acid prudent? Meta-analysis of randomised and large matched observational studies.Eur J Cardiothorac Surg. 2010 Jun;37(6):1375-83. doi: 10.1016/j.ejcts.2009.11.055. Epub 2010 Feb 1. Eur J Cardiothorac Surg. 2010. PMID: 20117944 Review.
Cited by
-
The effects of tranexamic acid on platelets in patients undergoing cardiac surgery: a systematic review and meta-analysis.J Thromb Thrombolysis. 2024 Feb;57(2):235-247. doi: 10.1007/s11239-023-02905-8. Epub 2023 Nov 14. J Thromb Thrombolysis. 2024. PMID: 37962715
-
Tranexamic acid reduces postoperative blood loss in Chinese pediatric patients undergoing cardiac surgery: A PRISMA-compliant systematic review and meta-analysis.Medicine (Baltimore). 2022 Mar 4;101(9):e28966. doi: 10.1097/MD.0000000000028966. Medicine (Baltimore). 2022. PMID: 35244062 Free PMC article.
-
A systematic review of the use of antifibrinolytic agents in pediatric surgery and implications for craniofacial use.Pediatr Surg Int. 2012 Nov;28(11):1059-69. doi: 10.1007/s00383-012-3167-6. Epub 2012 Sep 1. Pediatr Surg Int. 2012. PMID: 22940882
-
Comparison of aprotinin and tranexamic acid in adult scoliosis correction surgery.Eur Spine J. 2012 Jun;21(6):1121-6. doi: 10.1007/s00586-012-2205-3. Epub 2012 Mar 9. Eur Spine J. 2012. PMID: 22402839 Free PMC article.
-
Effectiveness of Prophylactic Tranexamic Acid in Reducing Blood Loss in Children Undergoing Open Nephrectomy for Wilms Tumor: A Randomized Controlled Study.Cureus. 2025 Jun 4;17(6):e85374. doi: 10.7759/cureus.85374. eCollection 2025 Jun. Cureus. 2025. PMID: 40621254 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources